Canadian Court Won't Shrink Paxil Birth Defect Class

Law360, New York (October 28, 2013, 4:58 PM EDT) -- A Canadian appeals court on Friday rejected GlaxoSmithKline Inc.’s efforts to significantly limit class certification on failure-to-warn issues in a suit claiming the antidepressant Paxil causes birth defects, siding with a 19-year class period over the three-year stretch the company sought.

The Court of Appeal for British Columbia tossed GSK’s appeal of a lower court order that certified a class of consumers who were prescribed Paxil between the date it was first sold in 1993 and the December 2012 class certification. The company had sought on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.